CN106474191A - Cinnamomum cassia extract and preparation method and its application in treatment of Parkinson disease - Google Patents
Cinnamomum cassia extract and preparation method and its application in treatment of Parkinson disease Download PDFInfo
- Publication number
- CN106474191A CN106474191A CN201611147553.5A CN201611147553A CN106474191A CN 106474191 A CN106474191 A CN 106474191A CN 201611147553 A CN201611147553 A CN 201611147553A CN 106474191 A CN106474191 A CN 106474191A
- Authority
- CN
- China
- Prior art keywords
- cassia tree
- chinese cassia
- extract
- chinese
- cinnamomum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 54
- 244000037364 Cinnamomum aromaticum Species 0.000 title claims abstract description 50
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 title claims abstract description 50
- 235000021511 Cinnamomum cassia Nutrition 0.000 title claims abstract description 49
- 238000011282 treatment Methods 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 13
- 238000000605 extraction Methods 0.000 title abstract description 5
- 241000522254 Cassia Species 0.000 claims abstract description 58
- 239000000706 filtrate Substances 0.000 claims abstract description 28
- 208000024891 symptom Diseases 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000007864 aqueous solution Substances 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 238000001035 drying Methods 0.000 claims abstract description 5
- 239000006228 supernatant Substances 0.000 claims abstract description 5
- 238000005119 centrifugation Methods 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 238000002386 leaching Methods 0.000 claims abstract description 4
- 230000008569 process Effects 0.000 claims abstract description 4
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- OOCCDEMITAIZTP-QPJJXVBHSA-N (E)-cinnamyl alcohol Chemical compound OC\C=C\C1=CC=CC=C1 OOCCDEMITAIZTP-QPJJXVBHSA-N 0.000 claims description 16
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 15
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 15
- 235000013985 cinnamic acid Nutrition 0.000 claims description 15
- 229930016911 cinnamic acid Natural products 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 10
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 claims description 9
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 claims description 9
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims description 9
- OOCCDEMITAIZTP-UHFFFAOYSA-N allylic benzylic alcohol Natural products OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 206010044565 Tremor Diseases 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 206010006100 Bradykinesia Diseases 0.000 claims description 5
- 208000006083 Hypokinesia Diseases 0.000 claims description 5
- 229960003638 dopamine Drugs 0.000 claims description 5
- 210000001259 mesencephalon Anatomy 0.000 claims description 5
- 210000003523 substantia nigra Anatomy 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 230000035614 depigmentation Effects 0.000 claims description 4
- 210000004558 lewy body Anatomy 0.000 claims description 4
- 210000001640 nerve ending Anatomy 0.000 claims description 4
- 210000002569 neuron Anatomy 0.000 claims description 4
- 239000000049 pigment Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 241000756943 Codonopsis Species 0.000 claims description 3
- 239000009636 Huang Qi Substances 0.000 claims description 3
- 244000241838 Lycium barbarum Species 0.000 claims description 3
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 210000000627 locus coeruleus Anatomy 0.000 claims description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 3
- 235000013824 polyphenols Nutrition 0.000 claims description 3
- 244000025254 Cannabis sativa Species 0.000 claims description 2
- 235000002789 Panax ginseng Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 230000000116 mitigating effect Effects 0.000 abstract description 4
- 238000010438 heat treatment Methods 0.000 abstract description 2
- 238000003809 water extraction Methods 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 7
- 239000013558 reference substance Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 206010034010 Parkinsonism Diseases 0.000 description 6
- 210000003414 extremity Anatomy 0.000 description 5
- 230000003319 supportive effect Effects 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 3
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000019479 dysautonomia Diseases 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003434 inspiratory effect Effects 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 208000018290 primary dysautonomia Diseases 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241001492222 Epicoccum Species 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 240000007164 Salvia officinalis Species 0.000 description 2
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical compound C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002242 deionisation method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000005412 red sage Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229960001032 trihexyphenidyl Drugs 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- PDWUPXJEEYOOTR-UHFFFAOYSA-N 2-[(3-iodophenyl)methyl]guanidine Chemical compound NC(=N)NCC1=CC=CC(I)=C1 PDWUPXJEEYOOTR-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 244000080208 Canella winterana Species 0.000 description 1
- 235000008499 Canella winterana Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010056696 Gaze palsy Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000025844 Prostatic disease Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010042241 Stridor Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 241001627955 Tetraodon lineatus Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000019558 anosmia Nutrition 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002262 ideomotor apraxia Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002746 orthostatic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 208000001282 primary progressive aphasia Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002804 pyramidal tract Anatomy 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a kind of cinnamomum cassia extract and preparation method and its application in treatment of Parkinson disease, including carrying out hot water extraction to Chinese cassia tree, obtains cinnamomum cassia extract.The cinnamomum cassia extract is that leaching process is with Chinese cassia tree as raw material（1）Chinese cassia tree raw material is crushed to 20 100 mesh by choosing, must crush Chinese cassia tree；（2）Add water in Chinese cassia tree to crushing, the crushing Chinese cassia tree aqueous solution made,（3）The heating of the Chinese cassia tree aqueous solution will be crushed, will be incubated 15 hours；（4）Centrifugation is separated by filtration, and collects supernatant, is former filtrate；（5）By former filtrate through reduced pressure concentration, filtrate must be concentrated；Filtrate drying will be concentrated and obtain cinnamomum cassia extract.Which has remarkable effect to improving Parkinsonian clinical symptoms, and using Chinese cassia tree, especially its extract has remarkable result to mitigating ailing, raising patients ' life quality.
Description
Technical field
The invention belongs to traditional Chinese medicine technology application, and in particular to a kind of cinnamomum cassia extract and preparation method and its in Parkinson's
Application in treatment.
Background technology
Parkinson's（PD）Also known as shaking plasy, it is one of modal nerve degenerative diseases.Epidemiology shows, illness rate
For 15～3,28/,100,000 populations,>65 years old crowds about 1%；The incidence of disease is 10～21/,100,000 populations/year.The PD cause of disease and pathogenesis
Not yet clearly, may be relevant with social factor, drug factors, patients factors etc..PD pathological change is：Substantia nigra of midbrain compact part is blue
Spot neuron depigmentation, black substance pigment is thin out and Lewy body occurs.PD nerve biochemical change be：Substantia nigra of midbrain compact part is blue
Spot N euron loss causes dopamine at above-mentioned position and its nerve endings（DA）Reduce,（DA produces PD clinic table when reducing >=70%
Existing）, and the acetylcholine in nigrostriatum system with DA function antagonism（ACH）Effect is relatively hyperfunction, and DA and ACH balance is lost
Adjust.
The modal clinical symptoms of Parkinson's have three kinds：Tremble, stiff, bradykinesia, early stage disease general not
Easily it is found, but clinically declines if there is fine activity, it is that not epithelium is pinched such as to make dumplings, chopsticks is taken not always when having a meal
Surely, or even some people occur sense of smell early stage and the symptom such as decline.At present, Parkinsonian treatment will adopt the means of complex treatment,
Mainly include drug therapy, operative treatment, rehabilitation, neuropsychological treatment etc..But existing medical technology wouldn't be effected a radical cure
Parkinson's.Treatment to patient, mainly from mitigating slight illness, delaying disease to develop, the quality of life for improving patient is set about.Therefore
One of emphasis for the treatment of can only adopt the Comprehensive rehabilitation based on kinesiatrics, improve patient's function, improve life matter
Amount.
Chinese cassia tree（Classification system：Cinnamomum cassia Presl）, it is the dry bark of canella Chinese cassia tree.Bark
Fragrance, can make spices, also be a kind of rare Chinese medicine.With the effects such as complement sun, warming spleen and stomach, removing internal cold, promoting blood circulation.Life can be controlled
Door fire declines, and cold weak pulse of limb, yang depletion are collapsed, and stomachache is had loose bowels, cold hernia run quickly globefish, waist and knee crymodynia, Amenorrhea abdominal mass, cloudy subcutaneous ulcer, streamer, and empty sun
Float more, heat in the upper and cold in the lower.Inventor is chancing on Chinese cassia tree and its extract pair to Chinese cassia tree and its extract when carrying out experimental study
Improve Parkinsonian clinical symptoms and there is remarkable effect, especially its extract is ailing to mitigation, improve patient using Chinese cassia tree
Quality of life has remarkable result.
Content of the invention：
The present invention discloses a kind of cinnamomum cassia extract and preparation method and its application in treatment of Parkinson disease, be first to Chinese cassia tree
Hot water extraction is carried out, obtains cinnamomum cassia extract.Which has remarkable effect to improving Parkinsonian clinical symptoms, outstanding using Chinese cassia tree
Which is that its extract has remarkable result to mitigating ailing, raising patients ' life quality.
A kind of cinnamomum cassia extract of the present invention, constitutes Chinese cassia tree polyphenol 30-60Wt% including following mass component, and cinnaman contains
Amount 20-40 Wt%, and cinnamic acid 0.1-5Wt%, cinnamic acid 0.01-1Wt%, cinnamyl alcohol 0.01-1Wt%, cumarin 0.01-
1Wt%, balance of Chinese cassia tree fiber.
It is another object of the present invention to a kind of preparation method of cinnamomum cassia extract, with Chinese cassia tree as raw material, leaching process is（1）
Chinese cassia tree raw material is crushed to 20-100 mesh by choosing, must crush Chinese cassia tree；（2）Add water in Chinese cassia tree to crushing, the crushing Chinese cassia tree aqueous solution made,
（3）The heating of the Chinese cassia tree aqueous solution will be crushed, will be incubated 1-5 hour；（4）Centrifugation is separated by filtration, and collects supernatant, is former filtrate；（5）
By former filtrate through reduced pressure concentration, filtrate must be concentrated；Filtrate drying will be concentrated and obtain cinnamomum cassia extract.
A kind of preparation method of cinnamomum cassia extract of the present invention, preferably 2）Described add water as deionized water, control is added
The amount of deionized water is 8-20 times of Chinese cassia tree quality, makes and crushes the Chinese cassia tree aqueous solution, 3）Control heating-up temperature is 40-90 DEG C.
It is preferred that a kind of preparation method of cinnamomum cassia extract, which 5）Former filtrate is concentrated into by the reduced pressure concentration, control
The 1/8-1/12 of former filtrate weight, must concentrate filtrate, the drying be will concentrate that filtrate is vacuum dried, heated-air drying or spraying
Dry cinnamomum cassia extract.
A kind of preparation method of the cinnamomum cassia extract, 1）Described crush Chinese cassia tree is Chinese cassia tree to be crushed to 60-100 mesh obtain
Crush Chinese cassia tree.
The present invention another object is that a kind of cinnamomum cassia extract and its preparation application or Chinese cassia tree in treatment of Parkinson disease are carried
Take the application of thing and its preparation and Chinese herb medicine in treatment of Parkinson disease.
Chinese herb medicine of the present invention is preferably the Radix Astragali, Radix Codonopsis, RADIX POLYGONI MULTIFLORI PREPARATA, matrimony vine, the red sage root, and cultivated land, by identical quality
Than being mixed.
The quality of each component of the Chinese herb medicine is preferably controlled to be respectively 10-20.
The present invention is preferably to play in the treatment of Parkinson disease improves following symptoms or one kind in pathological characters or many
Kind：
（1）Tremble,
（2）It is stiff,
（3）Bradykinesia,
（4）Substantia nigra of midbrain compact part Neurons of Locus Coeruleus depigmentation,
（5）Black substance pigment is thin out and Lewy body occurs,
（6）Dopamine at nerve endings（DA）Reduce.
A kind of cinnamomum cassia extract of the present invention, including following mass component Chinese cassia tree polyphenol 30-65Wt%, cinnaman content
20-45 Wt%, and cinnamic acid 0.1-5Wt%, cinnamic acid 0.01-1Wt%, cinnamyl alcohol 0.01-1Wt%, cumarin 0.01-1Wt% group
Point, balance of Chinese cassia tree fiber.Also include coumaric acid 0.01-0.5Wt% in cinnamomum cassia extract of the present invention.Which individually uses
Or the application that can be used in treatment of Parkinson disease is used together with Chinese herbal and crude drugs preparations, described Chinese herbal and crude drugs preparations is will be above-mentioned each
The Radix Astragali of component, Radix Codonopsis, RADIX POLYGONI MULTIFLORI PREPARATA, matrimony vine, the red sage root, the preparation that each 10-20 mass parts such as cultivated land are made in pharmacy are such as made
Aqua, aqua processed are prepared by the general aqua method processed of Chinese herbal medicine, and usage is same by existing Chinese herbal medicine aqua method with consumption.
The Chinese herbal medicine aqua that makes is used together for preventing and treating Parkinson disease therapeutic effect more preferably with cinnamomum cassia extract.
Above-mentioned cinnamomum cassia extract and its preparation are can be applicable in treatment Parkinson's preventing and treating, and preparation of the present invention is medicament
The formulations such as tablet in pharmacy, capsule, powder, pill made by preparation on, its through proper method.
The cinnamomum cassia extract of the present invention is that leaching process is with Chinese cassia tree as raw material（1）Chinese cassia tree raw material is crushed to 20- by choosing
100 mesh, must crush Chinese cassia tree；（2）Account for, to crushing to add in Chinese cassia tree, the water for crushing 8-20 times of weight of Chinese cassia tree；The water is deionization
Water, makes the crushing Chinese cassia tree aqueous solution,（3）The Chinese cassia tree aqueous solution will be crushed 40-90 DEG C is heated to, be incubated 1-5 hour；（4）Centrifugation or
It is separated by filtration, supernatant is collected, is former filtrate；（5）By former filtrate through being evaporated to the 1/8-1/12 of former filtrate weight, obtain dense
Contracting filtrate；（6）To concentrate that filtrate is vacuum dried, heated-air drying or be spray-dried to obtain cinnamomum cassia extract.Cinnamomum cassia extract is through suitable
When method makes the formulations such as tablet, capsule, powder, pill.
Cinnamomum cassia extract of the present invention can be used for Parkinsonian prevention and treatment, can improve following symptoms or pathology
In one or more：
（1）Tremble
（2）Stiff
（3）Bradykinesia
（4）Substantia nigra of midbrain compact part Neurons of Locus Coeruleus depigmentation
（5）Black substance pigment is thin out and Lewy body occurs
（6）Dopamine at nerve endings（DA）Reduce
It is presented herein below and utilizes cinnamomum cassia extract of the present invention or with Chinese herb medicine together for Parkinsonian prevention and treatment use feelings
Condition is described as follows.
Clinical efficacy is summarized：
General data：A kind of cinnamomum cassia extract is applied to clinical observation case 41,52-75 years old age, average year
64 years old age, wherein man 28, female 13.The course of disease -6 years 3 months.Control group 38, at 53-74 years old age, puts down
All 65 years old age, wherein male 25, female 13.The course of disease -6 years 6 months.
Diagnostic criteria：There is bradykinesia, and at least have that static tremor or this two masters tetanic levy one.Right
The inspection that all core masters levy must be unified Parkinson's according to MDS- and be assessed scale（MDS-UPDRS）Described in method
Carry out.
Once clarifying a diagnosis as parkinson's syndrome, diagnosed according to following standard：
Clinical definite Parkinson's（PD）Need to have：
1. absolute exclusion standard is not met
2. at least two supportive standards, and
3. sign is not warned（red flags）
It is diagnosed as being likely to PD needing to have：
1. absolute exclusion standard is not met；
2. if there is warning sign（red flags）Need to offset by supportive standard：
If there is 1 warning sign, it is necessary to need at least 1 supportive standard
If there is 2 warning signs, it is necessary to need at least 2 supportive standards
Note：Do not allow to occur more than 2 warning signs under the classification.
Explanation to above-mentioned several nouns：
1. supportive standard
（1）There is clear and definite and significant effective response to Dopaminergic Drugs treatment.During initial treatment, the function of patient is extensive
Answer normally or be close to normal level.In the case of clearly not recording, the notable response of initial treatment can be divided into following two feelings
Condition：
A. when drug dose increases, symptom is significantly improved, and during minimizing, symptom significantly increases；Slight change is not included.More than change
Objective scoring is crossed in accommodation（After treatment, UPDRS-III scoring improves more than 30%）Or it is subjective（Reliable patient or caregiver carry
The presence for being unequivocally established is significantly changed）Record；
B. clear and definite and significant " ON/OFF " phase fluctuates；Predictable dose of last phenomenon must be included to a certain extent.
（2）There is the unusual fluctuation disease of levodopa induction
（3）The single limbs static tremor of clinical examination record（The past or this inspection）
（4）There is anosmia or heart MIBG scintigraphy shows that there is heart goes sympathetic nerve to arrange
2. absolute exclusion standard
PD diagnosis is excluded by there is following any one：
（1）Clearly little abnormalities of brain, such as cerebella gait, limbs incoordination or cerebella eye are dynamic abnormal（Persistently stare
The nystagmus of induction, huge square wave jerk, the pan of the super rhythm and pace of moving things）
（2）Property gaze palsy on downward up rightness core, or the pan of selectively downward up rightness slows down
（3）In first 5 years of morbidity, behavior anomaly Frontotemporal dementia likely or primary progressive aphasia is diagnosed as
（According to the common recognition standard that delivers for 2011）
（4）Morbidity was still confined to the performance of the parkinson's syndrome of lower limb more than 3 years
（5）Treated using dopamine receptor antagonist or dopamine-depleting agents, and dosage and time course and drug-induced handkerchief
The gloomy syndrome of gold is consistent
（6）Although the state of an illness is at least moderate severity, but the levodopa treatment to high dose lacks observable treatment
Response
（7）The sensory deprivation of clear and definite cortex（As there is graphesthesia and reality in the case that primary sensing organ is complete
Body epicritic sensibility is damaged）, clear and definite limbs ideokinetic apraxia or progressive aphasia
（8）Presynaptic dopamine energy systemic-function neuroimaging checks normal
（9）Clearly recorded may result in parkinson's syndrome or the doubtful other diseases related to patients symptomatic, or based on whole
Body diagnostics is assessed, and professional assessment doctor feels may to be other syndromes, rather than PD
3. sign is warned（Red Flags）
（1）Occur the gait disorder of rapid progress in morbidity in 5 years, and need rule to use wheelchair
（2）Morbidity 5 years or more than 5 years, motor symptoms or sign are not in progress completely；Unless this be stably and treatment phase
Close
（3）The bulb dysfunction that early stage occurs：Serious dysphonia or dysarthrosis that morbidity occurred in 5 years（Big portion
Speech indigestion is waited in timesharing）Or serious dysphagia（The food for needing feed softer, or the feed of nose catheter, stomach fistulization）
（4）Inspiratory respiratory dysfunction：There is daytime or night inspiratory stridor or frequently inspiratory sigh
（5）Morbidity 5 years in there is serious dysautonomia, including：
A. after standing in 3 minutes, systolic pressure declines at least 30 mmHg or diastole drops to postural hypotension
There is no the disease of dehydration, other drugs treatment or possible explanation dysautonomia at least 15 mmHg, and patient；
B. morbidity 5 years in there is the serious retention of urine or the urinary incontinence（Do not include that women long-term or a small amount of pressure urine loses
Prohibit）, and be not simple FUNCTIONAL INCONTINENCE.For male patient, the retention of urine is not due to what prostatic disorders caused, and
Must be related to erectile dysfunction.
（6）Morbidity 3 years in due to balance infringement cause repeatedly（>1 times/year）Fall down
（7）There is disproportionately neck in 10 years and leans forward in morbidity（Myodystony）Or carpopedal contraction
（8）Even the course of disease to 5 years also occurs without any common non-motor symptoms, including sleep-disorder（Keep
Sleep disordered insomnia, excessive daytime sleepiness, rapid eye movement sleep behavioral disorder）, dysautonomia（Constipation, day
Between urgent urination, symptomatic orthostatic low blood pressure）, hyposphresia, phrenoblabia（Depressed, anxiety or illusion）
（9）The inexplicable pyramidal sign of other reasonses, is defined as pyramidal tract limb adynamia or clear and definite pathology sexual reflex is lived
Jump（Sole of the foot toe reaction including the slight asymmetric and isolatism of reflection）
The parkinsonism of bilateral symmetric property.Patient or caregiver are reported as bilateral onset, without any lateralization, and visitor
See physical examination and the other property in obvious side is also not observed
Usage and dosage：During clinical practice, treatment group adopts cinnamomum cassia extract, and per agent 0.6g containing cinnamomum cassia extract, one day is one,
30 doses be a course for the treatment of, early, middle and late three times before meals half an hour warm water take.Control group adopts benzhexol hydrochloride piece, starts one day 1
～2mg（0.5-1 piece）, often 3-5 day increase 2mg later（1）, to curative effect preferably and occurring without side reaction, one is not
More than 10mg（5）.
When being prevented and treated to parkinsonism using cinnamomum cassia extract, can be used alone, can yet be with above-mentioned medium-height grass
The aqua that medicine component is made to the prevention effect of parkinsonism more preferably, the usage of the preparation that said herbal medicine component is made with
Consumption is determined with consumption by existing above-mentioned each component usage.The above-mentioned treating dysfunction for being used equally to Parkinsonian correlation, prevention
Or delay its progress.
Criterion of therapeutical effect：Cure：Clinical symptoms are wholly absent；Effective：Clinical symptoms improve；Invalid：Clinical symptoms
Unchanged or increase.
Therapeutic effect：In clinical observation case, treatment group's 1-3 course for the treatment of of medication, cure 25, effective 15, no
Effect 1.There is no toxic and side effect during treatment.Control group cures 15, effective 20, invalid 3, occasionally has during treatment
The side effects such as dry, blurred vision, side effect after drug withdrawal disappear.This experimental result shows cinnamomum cassia extract for Parkinsonian
Therapeutic effect is better than benzhexol hydrochloride piece.
Description of the drawings：
Fig. 1, is the HPLC spectrogram of cinnamomum cassia extract prepared by the present invention；
Fig. 2, is the HPLC spectrogram of this coumaric acid, cumarin, cinnamyl alcohol, cinnamic acid and cinnamic acid mixing reference substance.
Explanation：The preparation of reference substance solution, is that precision weighs coumaric acid, cumarin, cinnamyl alcohol, cinnamic acid and cassia bark respectively
5.12 mg of sour reference substance, 7.31 mg, 14.27 mg, 12.50 mg, 4.44 mg, are respectively placed in 25 mL measuring bottles, plus methyl alcohol
Dissolve and scale is diluted to, shake up, make containing 0.2048 mg mL of coumaric acid-1, 0.2924 mg mL of cumarin-1, Chinese cassia tree
0.5708 mg mL of alcohol-1, 0.5000 mg mL of cinnamic acid-1With 0.1776 mg mL of cinnamic acid-1Reference substance deposit molten
Liquid, standby.Accurate coumaric acid, cumarin, cinnamyl alcohol, cinnamic acid and each 1mL of cinnamic acid reference substance stock solution of drawing is placed in 10
In mL volumetric flask, scale is diluted to mobile phase, obtain final product containing 0.02048 mg mL of coumaric acid-1, cumarin 0.02924
mg·mL-1, 0.05708 mg mL of cinnamyl alcohol-1, 0.05000 mg mL of cinnamic acid-1With 0.01776 mg mL of cinnamic acid-1
Reference substance mixed solution.
Sample solution：
The cinnamomum cassia extract for taking the present invention dries 4 h in vacuum drying chamber at 80 DEG C, precision weighs about 5 mg, is placed in 10 mL
Volumetric flask, with constant volume after flowing phased soln.All samples solution all with 0.45 m membrane filtration, enter for liquid chromatogram by filtrate
Sample is analyzed.
Chromatographic condition：
Chromatographic column is Kromasil C18 post（4.6 mm × 250 mm, 5 μm）；Mobile phase is methyl alcohol: water: phosphoric acid（45∶55∶
0.1, v/v/v）；0.8 mL min of flow velocity-1；280 nm of Detection wavelength；Column temperature is 30 DEG C；With coumaric acid, cumarin, cinnamyl alcohol,
Cinnamic acid and cinnamic acid meter, theoretical cam curve are all higher than 6000；The mixing of coumaric acid, cumarin, cinnamyl alcohol, cinnamic acid and cinnamic acid
Reference substance solution and cinnamomum cassia extract chromatogram.
Specific embodiment
Embodiment 1：Take after Chinese cassia tree 100kg is crushed to 60-100 mesh, Chinese cassia tree must be crushed；Deionization is added to crushing in Chinese cassia tree
Aqueous solution 800kg is mixed thoroughly, makes the crushing Chinese cassia tree aqueous solution, the crushing Chinese cassia tree aqueous solution that makes is heated to 50 DEG C and is extracted 3 hours,
And 2 hours are incubated, filter, supernatant is collected, is former filtrate, former filtrate reduced in volume to 100kg, vacuum drying are obtained Chinese cassia tree
Extract.The preparation cinnamomum cassia extract of above-mentioned preparation being prepared into by medical procedures in pharmacy.Such as take cinnamomum cassia extract to add
Starch and microcrystalline cellulose granulation, compressing tablet, per piece 0.2g containing cinnamomum cassia extract, especially 1-2 stage Parkinson sufferer of each stage
Person daily 3,30 days is a course for the treatment of.This product also can be taken by normal aging people as health products, for preventing Parkinson
Disease develops.
Claims (10)
1. a kind of cinnamomum cassia extract, constitutes Chinese cassia tree polyphenol 30-60Wt%, cinnaman content 20-40 including following mass component
Wt%, and cinnamic acid 0.1-5Wt%, cinnamic acid 0.01-1Wt%, cinnamyl alcohol 0.01-1Wt%, cumarin 0.01-1Wt%, balance of
Chinese cassia tree fiber.
2. a kind of cinnamomum cassia extract according to claim 1, also includes coumaric acid in cinnamomum cassia extract described in its feature
0.01-0.5Wt%.
3. a kind of preparation method of cinnamomum cassia extract, with Chinese cassia tree as raw material, leaching process is（1）Chinese cassia tree raw material is crushed to by choosing
20-100 mesh, must crush Chinese cassia tree；（2）Add water in Chinese cassia tree to crushing, the crushing Chinese cassia tree aqueous solution made,（3）Chinese cassia tree will be crushed water-soluble
Liquid is heated, and is incubated 1-5 hour；（4）Centrifugation is separated by filtration, and collects supernatant, is former filtrate；（5）Former filtrate is dense through reducing pressure
Contracting, must concentrate filtrate；Filtrate drying will be concentrated and obtain cinnamomum cassia extract.
4. a kind of preparation method of cinnamomum cassia extract according to claim 3, is characterized in that 2）Described add water as deionized water,
It is 8-20 times of Chinese cassia tree quality that control adds the amount of deionized water, makes the crushing Chinese cassia tree aqueous solution；3）Control heating-up temperature is 40-
90℃.
5. a kind of preparation method of cinnamomum cassia extract according to claim 3, is characterized in that 5）The reduced pressure concentration, control will
Former filtrate is concentrated into the 1/8-1/12 of former filtrate weight, must concentrate filtrate；The drying is that will to concentrate filtrate vacuum dried, hot
Air-dry dry or be spray-dried to obtain cinnamomum cassia extract.
6. a kind of preparation method of cinnamomum cassia extract according to claim 3, is characterized in that 1）Described by Chinese cassia tree crush be by
Chinese cassia tree is crushed to 60-100 mesh and must crush Chinese cassia tree.
7. application or cinnamomum cassia extract and its preparation and medium-height grass in treatment of Parkinson disease of a kind of cinnamomum cassia extract and its preparation
Application of the medicine in treatment of Parkinson disease.
8. application according to claim 7, is characterized in that the Chinese herb medicine for the Radix Astragali, Radix Codonopsis, RADIX POLYGONI MULTIFLORI PREPARATA, and matrimony vine is red
Ginseng, cultivated land, it is mixed by identical mass ratio.
9. application according to claim 8, is characterized in that controlling the quality of each component of the Chinese herb medicine to be respectively 10-
20.
10. application according to claim 7, it is characterized in that playing in the treatment of Parkinson disease improves following symptoms or disease
One or more in reason feature：
Tremble,
It is stiff,
Bradykinesia,
Substantia nigra of midbrain compact part Neurons of Locus Coeruleus depigmentation,
Black substance pigment is thin out and Lewy body occurs,
Dopamine at nerve endings（DA）Reduce.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611147553.5A CN106474191A (en) | 2016-12-13 | 2016-12-13 | Cinnamomum cassia extract and preparation method and its application in treatment of Parkinson disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611147553.5A CN106474191A (en) | 2016-12-13 | 2016-12-13 | Cinnamomum cassia extract and preparation method and its application in treatment of Parkinson disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106474191A true CN106474191A (en) | 2017-03-08 |
Family
ID=58284880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611147553.5A Pending CN106474191A (en) | 2016-12-13 | 2016-12-13 | Cinnamomum cassia extract and preparation method and its application in treatment of Parkinson disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106474191A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100058032A (en) * | 2008-11-24 | 2010-06-03 | 경희대학교 산학협력단 | A composition containing cinnamomum cassia extracts, its fractions or trans-cinnamaldehyde as an active ingredient isolated from cinnamomum cassia for the prevention and treatment of parkinson disease |
| CN103127466A (en) * | 2013-02-03 | 2013-06-05 | 于占彩 | Chinese medicine decoction for treating cognitive disorder of Parkinson disease |
-
2016
- 2016-12-13 CN CN201611147553.5A patent/CN106474191A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20100058032A (en) * | 2008-11-24 | 2010-06-03 | 경희대학교 산학협력단 | A composition containing cinnamomum cassia extracts, its fractions or trans-cinnamaldehyde as an active ingredient isolated from cinnamomum cassia for the prevention and treatment of parkinson disease |
| CN103127466A (en) * | 2013-02-03 | 2013-06-05 | 于占彩 | Chinese medicine decoction for treating cognitive disorder of Parkinson disease |
Non-Patent Citations (1)
| Title |
|---|
| 邹盛勤等: "RP-HPLC同时测定不同产地肉桂中5种成分的含量", 《光谱实验室》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN111743934A (en) | Traditional Chinese medicine composition for regulating intestinal flora and application thereof | |
| CN104958607A (en) | Traditional Chinese medicine composition for treating burning mouth syndromes of climacteric women and preparation method thereof | |
| CN102988905B (en) | Traditional Chinese medicine preparation for treating epilepsia and preparation method thereof | |
| CN102813780A (en) | Chinese herbal medicinal compound preparation used for treating macular degeneration of old people and preparation method thereof | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN102846824A (en) | Traditional Chinese medicinal composition for treating cold dampness blood stasis blocking channel type diabetic feet, and its preparation method | |
| CN100423754C (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
| CN103301431B (en) | Traditional Chinese medicinal preparation for treating glaucoma and preparation method thereof | |
| CN109865016A (en) | A kind of pharmaceutical composition and its preparation method and application for treating xerophthalmia | |
| CN111053854B (en) | Traditional Chinese medicine preparation with depression treatment effect and preparation method and application thereof | |
| CN103520643B (en) | A kind of Chinese medicine preparation being used for the treatment of diabetic cataract and preparation method thereof | |
| CN106474191A (en) | Cinnamomum cassia extract and preparation method and its application in treatment of Parkinson disease | |
| CN102793903B (en) | Preparation method of Chinese medicament for treating kidney-yang deficiency type acute glomerulonephritis | |
| CN105535587A (en) | Traditional Chinese medicinal preparation for treating heart and kidney disharmony type palpitation and insomnia and preparation method of traditional Chinese medicinal preparation | |
| CN104758578A (en) | Traditional Chinese medicine composition for treating palpitation | |
| CN103623189B (en) | A kind of Chinese traditional compound medicine and preparation method thereof of recession and reversal of atherosclerosis patch | |
| CN102793826B (en) | Traditional Chinese medicine for treating hypertension early-stage kidney damage and preparation method thereof | |
| CN106177461A (en) | A kind of Chinese medicine and western medicine compound preparation treating neurasthenic syndrome and preparation method | |
| CN104162112B (en) | A kind of pharmaceutical composition and preparation method thereof | |
| CN105535429A (en) | Traditional Chinese medicine for treating Parkinson's disease and preparation method thereof | |
| CN1211116C (en) | Medicine for treating sympthetic nerve disorder | |
| CN103356984B (en) | Traditional Chinese medicine composition for preventing and treating female iron deficiency anemia | |
| CN104258302A (en) | Traditional Chinese medicine for treating chronic idiopathic thrombocytopenic purpura due to fire excess from yin deficiency and preparation method of traditional Chinese medicine | |
| CN104825846A (en) | Traditional Chinese medicinal composition for treating facial neuritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170308 |